Ironwood PharmaceuticalsIRWD
About: Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Employees: 267
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
39,271% more call options, than puts
Call options by funds: $73.2M | Put options by funds: $186K
12% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 81
3.54% less ownership
Funds ownership: 111.42% [Q1] → 107.88% (-3.54%) [Q2]
13% less funds holding
Funds holding: 260 [Q1] → 227 (-33) [Q2]
26% less capital invested
Capital invested by funds: $1.52B [Q1] → $1.12B (-$400M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
60% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 55
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Leerink Partners Faisal Khurshid 67% 1-year accuracy 4 / 6 met price target | 14%upside $5 | Market Perform Initiated | 9 Sept 2024 |
Wells Fargo Mohit Bansal 57% 1-year accuracy 12 / 21 met price target | 173%upside $12 | Overweight Maintained | 9 Aug 2024 |
Craig-Hallum Chase Knickerbocker 50% 1-year accuracy 11 / 22 met price target | 127%upside $10 | Buy Maintained | 9 Aug 2024 |
